Cohen Courtney A, Zumbrun Elizabeth E, Writer James V, Bonagofski Luke G, Shoemaker Charles J, Zeng Xiankun, Blancett Candace D, Douglas Christina E, Delp Korey L, Taylor-Howell Cheryl L, Carey Brian D, Ravulapalli Suma, Raymond Jo Lynne, Dye John M, Herbert Andrew S
Viral Immunology Branch, Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Regulated Research Administration Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Viruses. 2024 Nov 21;16(12):1806. doi: 10.3390/v16121806.
The Ebola virus (EBOV) causes severe disease in humans, and animal models are needed to evaluate the efficacy of vaccines and therapeutics. While non-human primate (NHP) and rodent EBOV infection models have been well characterized, there is a growing need for an intermediate model. Here, we provide the first report of a small-particle aerosol (AE) EBOV ferret model and disease progression compared with the intramuscular (IM) EBOV ferret model. EBOV infection of ferrets by either route resulted in uniform lethality in 5-6.5 days post infection (dpi) in a dose-dependent manner, with IM-infected ferrets succumbing significantly earlier than AE-infected ferrets. EBOV disease progression differed between AE and IM routes, with significant viremia and presence of virus in target organs occurring earlier in the AE model. In contrast, significant fever, clinical signs of disease, liver pathology, and systemic inflammation occurred earlier in the IM EBOV model. Hepatocellular damage and splenic pathology were noted in both models, while pronounced lung pathology and renal impairment were exclusive to the AE and IM models, respectively. These results demonstrate that small-particle AE and IM ferret EBOV models share numerous common features with NHP and human EBOV infection by these routes and will therefore be useful for the development of vaccine and therapeutic countermeasures.
埃博拉病毒(EBOV)可导致人类患上严重疾病,因此需要动物模型来评估疫苗和治疗方法的疗效。虽然非人灵长类动物(NHP)和啮齿动物埃博拉病毒感染模型已得到充分表征,但对中间模型的需求日益增加。在此,我们首次报告了小颗粒气溶胶(AE)埃博拉病毒雪貂模型以及与肌肉注射(IM)埃博拉病毒雪貂模型相比的疾病进展情况。通过这两种途径感染雪貂的埃博拉病毒均在感染后5 - 6.5天内以剂量依赖的方式导致一致的致死率,肌肉注射感染的雪貂比气溶胶感染的雪貂死亡时间明显更早。气溶胶和肌肉注射途径的埃博拉病毒疾病进展有所不同,气溶胶模型中目标器官出现明显病毒血症和病毒的时间更早。相比之下,明显发热、疾病临床症状、肝脏病理变化和全身炎症在肌肉注射埃博拉病毒模型中出现得更早。两种模型均观察到肝细胞损伤和脾脏病理变化,而明显的肺部病理变化和肾功能损害分别是气溶胶模型和肌肉注射模型所特有的。这些结果表明,小颗粒气溶胶和肌肉注射雪貂埃博拉病毒模型与非人灵长类动物和人类通过这些途径感染埃博拉病毒有许多共同特征,因此将有助于疫苗和治疗对策的研发。